Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
US Department of Justice
Citi
McKinsey
AstraZeneca

Generated: April 19, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021549

« Back to Dashboard

NDA 021549 describes EMEND, which is a drug marketed by Merck, Msd Merck Co, and Merck And Co Inc, and is included in three NDAs. It is available from two suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EMEND profile page.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
Summary for 021549
Tradename:EMEND
Applicant:Merck
Ingredient:aprepitant
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021549
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMEND aprepitant CAPSULE;ORAL 021549 NDA Merck Sharp & Dohme Corp. 0006-0461 0006-0461-02 2 CAPSULE in 1 DOSE PACK (0006-0461-02)
EMEND aprepitant CAPSULE;ORAL 021549 NDA Merck Sharp & Dohme Corp. 0006-0461 0006-0461-06 1 BLISTER PACK in 1 CARTON (0006-0461-06) > 6 CAPSULE in 1 BLISTER PACK (0006-0461-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength80MG
Approval Date:Mar 26, 2003TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 26, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
Patent:➤ Try a Free TrialPatent Expiration:Sep 26, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength125MG
Approval Date:Mar 26, 2003TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 26, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY

Expired US Patents for NDA 021549

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
Teva
Julphar
Queensland Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.